In mouse model of NEC, C34 effectively reduced systemic inflammation.68 Another in vitro study showed that C34 suppresses LPS signaling in human ileum tissue resected from NEC infants.69 Therefore, C34 possesses significant potential as a therapeutic agent for treating TLR4-mediated inflammatory conditions such as NEC. This evidence concerns the gene TLR4 and necrotizing enterocolitis.